InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by Financière de la Montagne SARL SARL, Director. Insider active across 1 companies, notably Valerio Therapeutics. In total, 6 filings have been recorded. Total volume traded: €11k. The latest transaction was disclosed on 22 July 2025 — Souscription. Regulator: AMF. The full history is accessible without signup.
Declarations6 total
€2m33,470,016 shares@ €0.04613.9% of flow
ActionHors plateforme de négociation
2025DD1049404·
€1m27,777,777 shares@ €0.05413.6% of flow
ActionHors plateforme de négociation
2025DD1049394·
€2m7,142,857 shares@ €0.2818.1% of flow
ActionHors plateforme de négociation
2023DD915163·
€3m7,317,073 shares@ €0.4127.1% of flow
ActionHors plateforme de négociation
2022DD835531·
€10,95075,000 shares@ €0.1460.095% mcap0.1% of flow
Option d'achatHors plateforme de négociation
2021DD769766·
Ideal exit: 4 Jun 2022 (T+270)
€3m4,225,352 shares@ €0.7127.1% of flow
ActionHors plateforme de négociation
2021DD741766·
6 of 6 declarations
About Financière de la Montagne SARL SARL
Financière de la Montagne SARL, represented at Valerio Therapeutics by Nicolas Trebouta, is a key governance and capital partner of the listed French biotechnology company. Company filings and shareholder communications show that Financière de la Montagne has held a long-standing seat on the board and that its mandate was renewed at the general meeting of June 6, 2023. This underscores both continuity in governance and the board’s confidence in its contribution to the company’s strategic oversight. The entity is best understood as a long-term life-sciences investor rather than a traditional operating executive. Valerio Therapeutics’ reference documents state that Nicolas Trebouta, born on May 29, 1963, has been investing directly or through Financière de la Montagne in biotechnology companies since 2004. That track record suggests deep sector knowledge, familiarity with clinical development timelines, and the ability to support innovative companies through multiple financing and development cycles. Within Valerio Therapeutics, Financière de la Montagne has been repeatedly described as one of the company’s principal shareholders and a recurring source of financial support. Recent financial disclosures refer to shareholder funding, advances, and equity-linked support intended to strengthen liquidity, reduce pressure on the balance sheet, and sustain operations. In 2025, the company again appeared among the core financing partners alongside Artal International, reinforcing its role in helping stabilize the group during a demanding period for a clinical-stage biotech. From a corporate governance perspective, Financière de la Montagne combines board-level oversight with an investor’s discipline. Its presence on the board means it contributes to strategic decision-making, financial supervision, and the assessment of risks typical of a biotechnology company, including liquidity management, capital structure optimization, and support for clinical programs. This profile makes it a notable stakeholder in Valerio Therapeutics’ evolution, balancing patient long-term capital with active governance participation.
